KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Issued: 2009-2021

Historic Shares Issued for Halozyme Therapeutics (HALO) over the last 10 years, with Dec 2021 value amounting to $4.3 million.

  • Halozyme Therapeutics' Shares Issued fell 66.19% to $4.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $12.5 million, marking a year-over-year decrease of 80.22%. This contributed to the annual value of $14.1 million for FY2022, which is 12.08% up from last year.
  • As of Q4 2021, Halozyme Therapeutics' Shares Issued stood at $4.3 million, which was down 7.27% from $4.6 million recorded in Q3 2021.
  • Halozyme Therapeutics' Shares Issued's 5-year high stood at $135.3 million during Q2 2017, with a 5-year trough of -$602,000 in Q1 2021.
  • For the 3-year period, Halozyme Therapeutics' Shares Issued averaged around $7.5 million, with its median value being $4.6 million (2019).
  • As far as peak fluctuations go, Halozyme Therapeutics' Shares Issued plummeted by 237.89% in 2017, and later soared by 206,400.00% in 2018.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Shares Issued stood at -$1,000 in 2017, then spiked by 206,400.00% to $2.1 million in 2018, then spiked by 294.13% to $8.1 million in 2019, then skyrocketed by 56.78% to $12.7 million in 2020, then crashed by 66.19% to $4.3 million in 2021.
  • Its last three reported values are $4.3 million in Q4 2021, $4.6 million for Q3 2021, and $4.2 million during Q2 2021.